Technical Articles

The global peptide industry: manufacturing, CDMOs and supply chains

How to interpret market estimates, manufacturing capacity and international supply-chain documents within each source's scope.

2026-09-09 · 2 min read

Editorial educational content. Specialist review is not claimed; consult the original references and limitations.

Define the market before comparing figures

Therapeutics, development/manufacturing services and laboratory materials are not interchangeable statistical series. An estimate of the peptide-medicine market does not directly measure sales of research-use vials. Corporate revenue may also include platforms and modalities beyond peptides.

The Peptide Economy section identifies the publisher, period and forecast status of estimates. Its 2025 and 2030 figures from The Business Research Company belong to the same published series. Inconsistent segmentation and CAGR tables were not reproduced. Comparing reports would require compatible definitions and methodologies.

Specialized manufacturing roles

A program may distribute research, process development, testing and manufacturing among different organizations. CDMO and CRO describe roles in the ecosystem, not a quality standard automatically shared by every organization. Responsibility for a material remains tied to the relevant contract, entity, specification and documentation.

Installed capacity is different from a planned expansion. WuXi AppTec's disclosure about SPPS reactor volume concerns that company. It does not represent Bolang's capacity or establish a relationship between the organizations.

China and international trade

The WITS/UN Comtrade records used here concern imports of pharmaceutical products classified under HS chapter 30. They do not isolate peptides or necessarily include all pharmaceutical inputs. The original unit is thousands of US dollars; any conversion must remain auditable.

Do not add the European Union aggregate to its member countries again to construct a total. Keep the reporting period and flow direction explicit: a country's reported imports are not the same variable as a company's sales.

What corporate documents establish

Lilly's Form 10-K describes dependencies in parts of its supply chain. Chemitex reports cooperation with Zhejiang Jiuzhou. These are different document types: a corporate filing and a company's own news publication. Neither establishes purchases of Bolang material.

Apply this context to an inquiry

Use industry information to ask precise questions about origin, seller, preparation, transport and documentation. A quote should separate known product subtotals from freight, taxes, customs clearance and domestic delivery still to be confirmed. Sector scale does not replace due diligence concerning the specific product, batch and transaction terms.

Sources and verification scope

Commercial estimate · S01

Peptide Therapeutics Market Report 2026 ↗

The Business Research Company

Source details (original language)
Scope
Publisher estimate of peptide therapeutics, 2025–2030
Document section
Market overview; market size and growth forecast
Limitations
Not a research-material market or company revenue. Segmentation and CAGR inconsistencies were not imported.
Claim verification date
2026-09-09
Scientific publication · S04

Therapeutic peptides: current applications and future directions ↗

Wang et al. · Signal Transduction and Targeted Therapy

Source details (original language)
Scope
Review of therapeutic peptide development
Document section
Introduction; production, modification and applications
Limitations
Historical review, not validation of products or batches. More than 80 approved drugs is a 2022 literature statement.
Claim verification date
2026-09-09
Corporate disclosure · S07

Eli Lilly and Company Form 10-K, fiscal year 2025 ↗

SEC · filing by Eli Lilly and Company

Source details (original language)
Scope
Lilly reports reliance on China-based suppliers for portions of its supply chain
Document section
Manufacturing and supply, p. 21; third-party supply chain risk factors
Limitations
Does not identify Bolang, peptide purchases from Bolang, partnership, endorsement or certification.
Claim verification date
2026-09-09
Corporate disclosure · S08

WuXi AppTec expands global manufacturing capacity ↗

WuXi AppTec

Source details (original language)
Scope
Corporate statement: >100,000 L at end of 2025; expansion toward 130,000 L
Document section
SPPS reactor volume paragraph
Limitations
WuXi AppTec capacity only; target is not installed capacity. Not WuXi Biologics or Bolang.
Claim verification date
2026-09-09
Reported trade data · S05

Brazil pharmaceutical imports by partner, HS 30, 2025 ↗

WITS / UN Comtrade

Source details (original language)
Scope
Brazilian imports of pharmaceutical products, HS chapter 30
Document section
Reporter Brazil, partner China; trade value 1000 USD
Limitations
Not peptide-only, not all APIs, and not Bolang sales.
Claim verification date
2026-09-09
Reported trade data · S06

Pharmaceutical imports from China, HS 30, 2025 ↗

WITS / UN Comtrade

Source details (original language)
Scope
Reported pharmaceutical imports from China, HS chapter 30
Document section
United States and European Union rows; trade value 1000 USD
Limitations
Do not add EU aggregate to member countries. Not peptide-only trade.
Claim verification date
2026-09-09
Corporate disclosure · S11

Notícias: cooperação e presença global ↗

Chemitex

Source details (original language)
Scope
Chemitex reports cooperation with Zhejiang Jiuzhou
Document section
Cooperation announcement and Presença Global em 2025
Limitations
Self-reported cooperation, not transaction-level customs evidence. Geographic wording was not repeated.
Claim verification date
2026-09-09